Program
Aprepitant
Also written as “aprepitant”, “MK0869, aprepitant” and “Aprepitant Injection”.
Its studies are mostly in Depressive Disorder, Major · Vomiting · Nausea · Postoperative Nausea and Vomiting · Pruritus, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 210 open or running | phase 4since Sep 21, 2004 | May 2, 2002 | none ahead |
| CSPC Pharmaceutical Group | 11 open or running | phase 3since Jul 17, 2024 | Jul 17, 2024 | none ahead |
| Lahore Medical Research Center, LLP | 10 open or running | phase 3since Feb 23, 2024 | Feb 23, 2024 | none ahead |
| LEO Pharma | 10 open or running | phase 2since Sep 18, 2013 | Sep 18, 2013 | none ahead |
| Nuformix Technologies | 10 open or running | phase 1since Mar 20, 2019 | Mar 20, 2019 | none ahead |
| Ono Pharmaceutical | 10 open or running | phase 2since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| Qilu Pharmaceutical | 10 open or running | phase 3since Apr 10, 2025 | Apr 10, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 12 studies since May 2, 2002.
- Sep 13, 2005Ono Pharmaceutical's first study: phase 2 study in NeoplasmsNew to Ono PharmaceuticalOno Pharmaceutical · NCT00212602 · 420 enrolled · Japan
- Jun 14, 2006Phase 3 study in VomitingMerck · NCT00337727 · 848 enrolled
- Jan 6, 20092 phase 1 studiesMerck · NCT00818259, NCT00819039
- Jul 23, 2009Phase 1 study in VomitingMerck · NCT00945321 · 42 enrolled
- Jul 31, 2009Phase 3 study in VomitingMerck · NCT00952341 · 421 enrolled
- Oct 6, 2009Phase 1 study in VomitingMerck · NCT00990821 · 188 enrolled
- May 26, 2011Phase 3 study in VomitingMerck · NCT01362530 · 307 enrolled
- Jul 5, 2012Phase 4 study in NauseaMerck · NCT01636947 · 494 enrolled
- Nov 19, 2012Phase 2 study in Post-operative NauseaMerck · NCT01732458 · 229 enrolled
- Sep 18, 2013LEO Pharma's first study: phase 2 study in PruritusNew to LEO PharmaLEO Pharma · NCT01963793 · 20 enrolled · Germany
- Mar 20, 2019Nuformix Technologies's first study: phase 1 study in HealthyNew to Nuformix TechnologiesNuformix Technologies · NCT03889366 · 12 enrolled · United Kingdom
- Feb 23, 2024Lahore Medical Research Center, LLP's first study: phase 3 study in Primary DysmenorrheaNew to Lahore Medical Research Center, LLPLahore Medical Research Center, LLP · NCT06317064 · 40 enrolled · Pakistan
- Jul 17, 2024CSPC Pharmaceutical Group's first study: phase 3 study in VomitingNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT06543966 · 486 planned
- Apr 10, 2025Qilu Pharmaceutical's first study: phase 3 study in Postoperative Nausea and VomitingNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT06932107 · 518 enrolled · China
TargetBeta
“Neurokinin 1 receptor antagonist”ChEMBL 37, by rule
Other programs on TACR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| elinzanetantrule | Bayer | phase 3 | 24 |
| tradipitantrule | Vanda Pharmaceuticals | phase 3 | 19 |
| fosnetupitantrule | Helsinn Healthcare | phase 3 | 2 |
| HRS5580 | Jiangsu HengRui Medicine | phase 2 | 2 |
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06932107Postoperative Nausea and Vomiting · China | 3 | Completed | Qilu Pharmaceutical | May 28, 2024 | 518 |
| NCT06543966Vomiting | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Mar 28, 2026 | 486 |
| NCT06317064Primary Dysmenorrhea · Pakistan | 3 | Completed | Lahore Medical Research Center, LLP | Oct 31, 2024 | 40 |
| NCT03889366Healthy · United Kingdom | 1 | Completed | Nuformix Technologies | Apr 15, 2019 | 12 |
| NCT01963793Pruritus · Germany | 2 | Completed | LEO Pharma | Jul 2014 | 20 |
| NCT01732458Post-operative Nausea | 2 | Completed | Merck | Sep 26, 2016 | 229 |
| NCT01636947Nausea | 4 | Completed | Merck | Aug 4, 2014 | 494 |
| NCT01362530Vomiting | 3 | Completed | Merck | Mar 14, 2013 | 307 |
| NCT00990821Vomiting | 1 | Completed | Merck | Dec 2005 | 188 |
| NCT00952341Vomiting | 3 | Completed | Merck | Apr 4, 2010 | 421 |
| NCT00945321Vomiting | 1 | Completed | Merck | Mar 2009 | 42 |
| NCT00819039Postoperative Nausea and Vomiting · United States, Brazil, Mexico and more | 1 | Completed | Merck | Mar 12, 2013 | 98 |
| NCT00818259Vomiting | 1 | Terminated | Merck | Jan 20, 2014 | 92 |
| NCT00337727Vomiting | 3 | Completed | Merck | Oct 28, 2008 | 848 |
| NCT00212602Neoplasms · Japan | 2 | Completed | Ono Pharmaceutical | 420 | |
| NCT00092196Nausea | 3 | Completed | Merck | Dec 1, 2004 | 820 |
| NCT00092183Nausea | 4 | Completed | Merck | Dec 1, 2003 | 866 |
| NCT00080444Vomiting | 3 | Completed | Merck | Sep 2006 | 50 |
| NCT00048607Depressive Disorder, Major | 3 | Completed | Merck | Dec 31, 2003 | 600 |
| NCT00048594Depressive Disorder, Major | 3 | Completed | Merck | Dec 18, 2003 | 800 |
| NCT00042029Depressive Disorder, Major | 3 | Completed | Merck | Oct 3, 2003 | 324 |
| NCT00035295Depressive Disorder, Major | 3 | Completed | Merck | Dec 5, 2003 | 584 |
| NCT00035282Depressive Disorder, Major | 3 | Completed | Merck | Dec 2003 | 450 |
| NCT00035048Depressive Disorder, Major | 3 | Completed | Merck | Dec 29, 2003 | 540 |
| NCT00035009Depressive Disorder, Major | 3 | Completed | Merck | Dec 22, 2003 | 468 |
| NCT00034983Depressive Disorder, Major | 3 | Completed | Merck | Dec 29, 2003 | 900 |
| NCT00034944Depressive Disorder, Major | 3 | Completed | Merck | Dec 17, 2003 | 495 |
How it is read
Names in the registry
- “aprepitant”, 8 entries
- “Aprepitant”, 4 entries
- “MK0869, aprepitant”, 4 entries
- “Aprepitant Injection”, 2 entries
- “Aprepitant 125 mg”, 2 entries
Codes read as this program: MK0869.
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 9 studies
- Vomiting, 7 studies
- Nausea, 4 studies
- Postoperative Nausea and Vomiting, 3 studies
- Pruritus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.